Serialization software player Adents has wrapped up a $13 million round to expand its partnership program in the U.S. and break into new markets.
Bionext has picked up Rhenovia Pharma's cell signaling modeling technology and the R&D team that developed it to form a subsidiary, TheraScape.
Merck KGaA has given Orange Business Services responsibility for redesigning and optimizing the computer network that links its 200 locations.
Bioclinica has added remote clinical trial technology used by Roche and Johnson & Johnson to its cloud platform.
Genedata has landed a deal with Evotec, continuing a busy 18-month period in which it has signed up Bayer, Boehringer Ingelheim and Merck KGaA.
Novartis has turned to Cure Forward's matchmaking tool for patients and trial recruiters for help identifying potential participants for its cancer…
Forentis Fund has committed $7.5 million to Blueprint Bio, a firm focused on identifying, validating and marketing biomarkers.
Mount Sinai has reported a jump in enrollment in a Phase III trial of a Bayer drug after it used natural language processing to sift through EHRs.
Microsoft and Median Technologies have teamed up to develop a cloud computing-powered image analysis technology capable of detecting cancer early.
Pfizer has signed up to use clinical trial technologies from Oracle, a company it has stuck with as its Big Pharma peers have defected to Medidata.